Biologics, Contract Manufacturing, Biodefense
Total Trials
62
As Lead Sponsor
45
As Collaborator
17
Total Enrollment
937,444
NCT00053482
Dose Study of ACAM2000 Smallpox Vaccine in Previously Vaccinated Adults
Phase: Phase 2
Role: Lead Sponsor
Start: Jan 31, 2003
Completion: Oct 31, 2003
NCT00053495
Effect of Dose, Safety, Tolerability of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination
Completion: Nov 30, 2003
NCT00877656
HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma
Phase: Phase 2/3
Start: Aug 31, 2005
Completion: Dec 31, 2008
NCT00360737
Safety Study of 7 Botulinum Antitoxin Serotypes Derived From Horses
Phase: Phase 1
Start: Jul 31, 2006
Completion: Apr 30, 2010
NCT00893516
CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma
Start: May 31, 2007
NCT00448253
Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum
Start: Jul 31, 2007
Completion: Sep 30, 2008
NCT01374984
VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection
Phase: N/A
Start: Aug 31, 2007
Completion: Aug 31, 2027
NCT02016963
An Open-label, Nonrandomized Study to Evaluate the Safety and Immunogenicity of Raxibacumab With Reinjection
Role: Collaborator
Start: Jan 31, 2008
Completion: May 31, 2008
NCT00636519
Botulism Antitoxin Effects on Paralysis Induced by Botulinum Neurotoxins in the EDB Muscle
Start: Feb 29, 2008
Completion: Oct 31, 2009
NCT00639678
A Study to Evaluate the Safety and Tolerability of Raxibacumab in Healthy Subjects
Phase: Phase 3
Start: Mar 31, 2008
NCT00679172
Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults
Start: May 31, 2008
NCT00927719
Safety Surveillance Study of ACAM2000® Vaccinia Vaccine
Start: Dec 31, 2008
Completion: Dec 31, 2017
NCT00928577
Safety Surveillance Cohort Study of Vaccinia Vaccine (ACAM2000®)
Completion: Dec 31, 2015
NCT00845650
Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)
Phase: Phase 1/2
Start: Feb 28, 2009
Completion: Oct 31, 2010
NCT01311674
Hepatitis B Virus Antibody Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)
Start: Sep 30, 2009
Completion: Mar 11, 2011
NCT01540929
Post-licensure Department of Defense (DOD) Screening Accuracy Study in Military Personnel
Completion: Sep 30, 2012
NCT01006798
Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1
Start: Oct 31, 2009
Completion: Sep 30, 2011
NCT01202695
Safety and Pharmacokinetics Study of Human Monoclonal Antibody (AVP-21D9)
Start: Aug 31, 2010
Completion: Jun 30, 2011
NCT01158157
VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV
Start: Sep 13, 2010
Completion: Feb 14, 2012
NCT01263691
Safety, Tolerability and Immunogenicity Study of AV7909 Anthrax Vaccine in Healthy Adults
Start: Dec 31, 2010
Completion: Jun 30, 2012
NCT01395082
ACAM2000® Myopericarditis Registry
Start: Apr 30, 2011
Completion: Feb 4, 2019
NCT01491607
Immunogenicity and Safety Study of a Three-Dose BioThrax® Regimen for Post-Exposure Prophylaxis in Healthy Adults
Start: Nov 30, 2011
Completion: May 31, 2012
NCT01585181
Safety and Immunogenicity of the Live Oral Cholera Vaccine Candidate PXVX0200
Start: Apr 30, 2012
Completion: Jan 31, 2013
NCT01653392
BioThrax® (Anthrax) Vaccine in Pregnancy Registry
Start: Jul 31, 2012
Completion: Feb 29, 2020
NCT01683773
Safety Study of Tuberculosis Vaccines AERAS-402 and MVA85A
Start: Sep 30, 2012
Completion: Aug 31, 2014
NCT01753115
Ciprofloxacin BioThrax Co-Administration Study
Start: Dec 31, 2012
Completion: Aug 31, 2013
NCT01770743
A Phase 2 Safety and Immunogenicity Study for an Anthrax Vaccine Using 3 Schedules and Two Dose Levels
Start: Jan 31, 2013
Completion: Dec 31, 2014
NCT01895855
Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera
Start: Sep 30, 2013
Completion: Nov 30, 2014
NCT01989533
Study of Safety and Immunogenicity of HIV Vaccines in Healthy Volunteers
Start: Nov 19, 2013
Completion: Apr 8, 2019
NCT01979406
A Phase 1 Ascending Dose Study to Assess the Safety and Immunogenicity of Adenovirus Anthrax Vector Candidate Vaccines
Start: Nov 30, 2013
Completion: Sep 30, 2015
NCT02094586
A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults
Start: May 31, 2014
Completion: Jun 30, 2015
NCT02100631
A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults
NCT02061358
Study to Determine the Safety, Tolerability and Pharmacokinetics of UV-4B Solution Administered Orally in Healthy Subjects
Start: Jul 31, 2014
NCT02145377
PXVX0200 (CVD103-HgR) vs Shanchol in Mali
Completion: Mar 31, 2015
NCT02051062
BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients
Phase: Phase 4
Start: Oct 31, 2014
Completion: Jul 31, 2027
NCT02055183
BT-010 Registry for the Evaluation of Safety and Clinical Outcomes in Patients Treated With Botulinum Antitoxin
Completion: Jul 31, 2017
NCT02339155
Effect of Raxibacumab on Immunogenicity of Anthrax Vaccine Adsorbed
Start: Feb 24, 2015
Completion: Jun 6, 2017
NCT02771730
Study to Evaluate the Safety and Immunogenicity of an Oral HIV Vaccine in Healthy, HIV-uninfected Adults
Start: Mar 31, 2015
Completion: Feb 28, 2017
NCT02391909
Phase 4 Study To Assess The Safety Of Vivotif At Different Release Titers Among Travelers
Start: Aug 26, 2015
Completion: Feb 21, 2017
NCT02443623
VA-008 ACAM2000® Vaccination of Plasma Donors for the Production of VIGIV
Start: Sep 30, 2015
Completion: Aug 31, 2021
NCT02696291
Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects
Start: May 27, 2016
Completion: Mar 2, 2017
NCT03160339
A Study to Assess the Safety, Pharmacodynamics, and Immunogenicity of PXVX0047
Start: May 1, 2017
Completion: Nov 27, 2017
NCT03220737
VAXCHORA Pediatric Study to Assess Safety and Immunogenicity
Start: Jul 21, 2017
Completion: Mar 6, 2020
NCT03315104
Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A
Start: Nov 17, 2017
Completion: Jun 17, 2019
NCT03425149
Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults
Start: Feb 24, 2018
Completion: Nov 16, 2018
NCT03483961
Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults
Start: Apr 18, 2018
Completion: Sep 21, 2020
NCT03624946
Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)
Start: Jun 27, 2018
Completion: Mar 6, 2019
NCT03877926
VELOCITY: An Anthrax Vaccine Clinical Study
Start: Mar 11, 2019
Completion: Aug 6, 2020
NCT04067011
Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study
Start: Aug 12, 2019
Completion: Mar 19, 2020
NCT03992872
Phase 2 Open-label Study of Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317)
Start: Nov 20, 2019
Completion: Jan 19, 2021
NCT04661839
A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults
Start: Dec 24, 2020
Completion: Jul 27, 2021
NCT05072080
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317 (CHIKV VLP Vaccine)
Start: Sep 29, 2021
Completion: Apr 3, 2023
NCT05065983
A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine
Start: Oct 11, 2021
Completion: May 5, 2022
NCT05155319
Universal Influenza A Vaccine in Healthy Adults
Start: Dec 1, 2021
Completion: Oct 10, 2023
NCT05142306
A COVID-19 Study to Evaluate Safety and PK of COVID-HIG Administered Through IM, SC, or IV Routes to SARS-CoV-2 Uninfected Adults
Start: Dec 7, 2021
Completion: May 31, 2022
NCT05194358
Study of SIAN Nasal Spray in Healthy Adults
Start: Dec 21, 2021
Completion: Oct 13, 2023
NCT05377255
Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults
Start: Mar 28, 2022
Completion: May 10, 2022
NCT05349617
Safety and Immunogenicity of CHIKV VLP Vaccine PXVX0317 in Adults ≥65 Years
Start: May 12, 2022
Completion: Aug 8, 2023
NCT05935917
Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adults
Start: May 30, 2023
Completion: Sep 27, 2023
NCT03569514
Observational Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Patients With Systemic Anthrax
Start: Nov 30, 2025
Completion: Jul 31, 2026
NCT03569553
A Field Study Evaluating Clinical Benefit and Safety of AIGIV (ANTHRASIL®) in Inhalational Anthrax Patients
Start: May 30, 2026
NCT02177721
Clinical Benefit and Safety of Raxibacumab in Patients With Symptomatic Inhalational Anthrax in a Mass Exposure Scenario
Start: May 31, 2026
Completion: Dec 31, 2035
Loading map...